⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Byondis and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Byondis
↗Nijmegen, Netherlands
Byondis is an independent, fully integrated clinical-stage biopharmaceutical company based in the Netherlands. It focuses on the research, development, and manufacturing of innovative targeted medicines, particularly antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs), to address unmet medical needs in oncology and autoimmune diseases.
The company operates a state-of-the-art campus in Nijmegen, which includes in-house R&D and GMP manufacturing facilities. Byondis leverages proprietary technologies, such as its duocarmazine linker-drug (LD) platform (ByonZine®) and site-specific conjugation technology (ByonShieLD®), to create next-generation precision medicines.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2012
Ownership:private
Status:operating
FUNDING
Investors:Aglaia
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Antibody-drug conjugates (ADCs), Monoclonal antibodies (mAbs), New chemical entities (NCEs)
Active Trials:14
Trial Phases:Phase 1: 14
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Byondis Holding B.V.
Key Partnerships:Academic research institutions (e.g., Radboud University), Global biotech and pharma companies (collaborative R&D)
COMPETITION
Position:Emerging
Competitors:Antheia, Synthego
LEADERSHIP
Key Executives:
Christoph Korpus - CEO
Jacques Lemmens - Founder / Chairman of the Board
Wim Dokter - Chief Scientific Officer
Scientific Founders:Jacques Lemmens
Board Members:Jacques Lemmens
LINKS
Website:byondis.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Byondis. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.